WASHINGTON — President Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies joining the 17 that reached agreements with the administration previously.
The new companies striking deals — Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB — made pledges similar to those made by larger drugmakers before them: to sell new medications to U.S. patients at prices comparable to the lowest prices in peer countries, to offer their drugs to state Medicaid programs at “most-favored nation” prices, and, in some instances, to bolster domestic manufacturing and contribute to the U.S. medical stockpiles. In return, it’s believed at least some of the companies will avoid tariffs.
UCB, Sun Pharma, Teva, and Astellas will, together, contribute 290 metric tons of active pharmaceutical ingredients to the country’s strategic reserves as part of the deals. All of the new companies except BridgeBio are headquartered outside of the U.S.
